Jacquet Eric G, Schanie Carrie L, Fugier-Vivier Isabelle, Willer Sharon S, Ildstad Suzanne T
Institute for Cellular Therapeutics, University of Louisville, Louisville, KY 40202-1760, USA.
Pediatr Transplant. 2003 Oct;7(5):348-57. doi: 10.1034/j.1399-3046.2003.00100.x.
Graft rejection and the toxicity associated with the use of non-specific immunosuppression remain the major limitations in pediatric solid organ transplantation. The induction of tolerance in transplant recipients is an elusive but achievable goal that will decrease the dependence on immunosuppressive agents. BMT is associated with a robust form of donor-specific transplantation tolerance. It achieves a state of chimerism, defined as the presence of donor marrow cells in the recipient. The two major toxicities in conventional bone marrow transplantation that have prevented its clinical application to induce tolerance are the toxicity of ablative conditioning and GVHD. Two forms of chimerism exist: full chimerism and mixed chimerism. In full chimerism, the hematopoietic system of the recipient is replaced by that of the donor following ablative conditioning. Full chimerism is associated with a relatively impaired immunocompetence for primary immune responses and an increased risk of GVHD. In addition, the 7-10% regimen-related mortality associated with ablation could not be accepted in solid organ allograft recipients. In mixed chimerism the donor hematopoietic system co-exists with that of the recipient. Mixed chimerism induces donor-specific tolerance and is associated with superior immunocompetence and a relative resistance to GVHD compared with full chimerism. Moreover, it can be achieved with partial conditioning, thereby reducing the regimen-related morbidity associated with myeloablation. Approaches to establish mixed chimerism using non-myeloablative-conditioning regimens have been aggressively pursued over the past decade. Mixed chimerism can be safely established with minimal conditioning, resulting in a significant reduction in risk compared with ablative conditioning. GVHD is the final hurdle that has prevented the widespread application of chimerism to induce tolerance. Donor T cells are the primary effector cells for GVHD. Although T cell depletion of the donor marrow avoids GVHD, it results in an increase in the rate of graft failure in MHC-disparate recipients. The dichotomy between GVHD and T cell depletion graft failure has recently been dissociated by the discovery of CD8+/TCR- graft FC. Purified HSC engraft readily in syngeneic recipients but not in MHC-disparate allogeneic recipients. The addition of small numbers of facilitating cells permits durable HSC engraftment in allogeneic recipients and avoids GVHD. Using FC to promote HSC engraftment following non-myeloablative conditioning could be a promising approach to establish tolerance in solid organ transplantation. This invited review focuses on recent developments in stem cell chimerism and tolerance that could bring the use of this approach to induce tolerance to solid organ transplantation one step closer to reality.
移植物排斥反应以及与使用非特异性免疫抑制相关的毒性仍然是小儿实体器官移植的主要限制因素。在移植受者中诱导免疫耐受是一个难以实现但可以达成的目标,这将减少对免疫抑制剂的依赖。骨髓移植(BMT)与一种强大的供体特异性移植耐受形式相关。它实现了一种嵌合状态,定义为受者体内存在供体骨髓细胞。传统骨髓移植中阻碍其临床应用以诱导耐受的两种主要毒性是清髓预处理的毒性和移植物抗宿主病(GVHD)。存在两种嵌合形式:完全嵌合和混合嵌合。在完全嵌合中,清髓预处理后受者的造血系统被供体的造血系统所取代。完全嵌合与原发性免疫反应的免疫能力相对受损以及GVHD风险增加相关。此外,实体器官同种异体移植受者无法接受与清髓相关的7 - 10%的方案相关死亡率。在混合嵌合中,供体造血系统与受者的造血系统共存。与完全嵌合相比,混合嵌合诱导供体特异性耐受,并与更好的免疫能力和对GVHD的相对抗性相关。此外,它可以通过部分预处理实现,从而降低与骨髓消融相关的方案相关发病率。在过去十年中,人们积极探索使用非清髓性预处理方案建立混合嵌合的方法。通过最小化预处理可以安全地建立混合嵌合,与清髓预处理相比,风险显著降低。GVHD是阻碍嵌合广泛应用以诱导耐受的最后一道障碍。供体T细胞是GVHD的主要效应细胞。虽然对供体骨髓进行T细胞清除可避免GVHD,但这会导致MHC不相合受者中移植物失败率增加。最近,通过发现CD8 + /TCR - 移植物FC,GVHD与T细胞清除导致的移植物失败之间的二分法已被打破。纯化的造血干细胞(HSC)很容易在同基因受者中植入,但在MHC不相合的异基因受者中则不然。添加少量辅助细胞可使HSC在异基因受者中持久植入并避免GVHD。使用FC在非清髓性预处理后促进HSC植入可能是在实体器官移植中建立耐受的一种有前景的方法。这篇特邀综述重点关注干细胞嵌合和耐受的最新进展,这些进展可能使使用这种方法诱导实体器官移植耐受更接近现实。